ArticleCureus2026
Intracranial Hemorrhage as a Life-Threatening Complication of Congenital Factor VII Deficiency Associated With Inhibitor Development: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital factor VII (FVII) deficiency is an uncommon autosomal recessive bleeding disorder with highly variable clinical expression. Although most patients present with mild to moderate bleeding symptoms, severe cases may manifest with life-threatening hemorrhage, particularly intracranial bleeding. The emergence of inhibitors against exogenous FVII is exceedingly rare but poses a significant therapeutic challenge because of treatment refractoriness and an increased risk of major bleeding. We describe a five-year-old Saudi girl with severe congenital FVII deficiency diagnosed in the neonatal period who developed inhibitory antibodies while on regular recombinant activated FVII (rFVIIa) prophylaxis. She presented with acute intracranial hemorrhage and was successfully managed with rFVIIa despite the presence of a high-titer inhibitor. This report highlights the importance of early recognition of inhibitor development in FVII deficiency and the need for individualized therapeutic approaches in rare bleeding disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.